- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03024762
Active Search for Pediatric HIV/AIDS (ASPA) (ASPA)
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Introduction: Globally in 2014, the antiretroviral therapy (ART) coverage rate amongst children was 32% against 41% in adults, and in Cameroon this gap was even wider (10.4% % vs 28%). Identifying and linking children to care are key barriers to effective expansion of pediatric ART in resources-limited settings. To identify HIV-infected children and enroll positive cases in care, the World Health Organization (WHO) recommended in 2007, the provider-initiated-testing and counseling (PITC) strategy. The blanket PITC (bPITC), whereby all children consulting in the health facility have to be screened for HIV requires a lot of resources in terms of HIV testing kits and supplies in addition to the increased workload on the already overburden health personnel in resource-limited settings. Conversely, the targeted PITC approach (tPITC) where children born to HIV-infected parents are offered HIV testing and counseling seems more feasible and effective. The primary objective of this study is to assess the effectiveness of tPITC in comparison with bPITC in case detection of HIV-infected children and adolescents. The secondary objective is to assess the acceptability and feasibility of tPITC in comparison with bPTIC among children and adolescents in Cameroon.
Methods:
Design: The investigator will conduct in 3 health facilities a non-randomized controlled pragmatic trial comparing the effectiveness of the targeted (intervention arm) against the blanket PITC (control arm) in case finding and linkage of HIV-infected children and adolescents in HIV treatment.
Study population: For the intervention arm, the study population will be children and adolescents between 6 weeks to 19 years born to HIV-infected parents and the control arm will be children of the same age group seeking care in the hospital irrespective of the motive of consultations.
Procedure: The study will be implemented in the Limbe Regional Hospital (South West Region), the Abong-Mbang District Hospital (East Region) and the Ndop District Hospital (North West Region) in Cameroon for a period of 36 months. Prior to the conduct of the study, health facility staff will be trained in PITC implementation. Testing kits and supplies will be made available to the site. Enrolment in the 2 arms will be done simultaneously till completion of the sample size. The HIV testing and ART eligibility assessment will be done following the national guidelines.
Sample size calculation: Based on the results of the pilot of this targeted PITC, we believe that with its implementation, the yield of newly diagnosed HIV cases amongst children should at least equal the double of the yield the blanket PITC (control arm) in same health facility. Therefore, the investigators have calculated the sample size to detect the minimum effect in the intervention group equal to at least the double of the yield in the control arm. Computing the formula for sample size calculation of 2 independent samples, we obtained a sample size of 435 children per arm. Hence a total sample size of 870 children.
Data collection, management and analysis: Socio-demographic data for children and parents, HIV status and ART eligibility, linkage to care and HIV treatment outcome will be collected using standardized pre-tested questionnaires. A database will be developed on Microsoft Access for data entry. Data entry will be done progressively till the study sample size is attained. Data analysis will be done using SPSS software and findings will be reported using both descriptive and analytical statistics.
Ethical considerations: Parents' informed consent and children' assent will be required for enrollment into the study. The study will obtain an ethical clearance prior to implementation.
Outcome: This study will assess the effectiveness of targeted PITC in case identification and linkage of HIV-infected children to care/treatment. This new knowledge could be used to reduce the current global gap in pediatric and adolescent HIV treatment.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Limbe, Kamerun
- Limbe Regional Hospital
-
-
East
-
Abong Mbang, East, Kamerun
- Abong-Mbang District Hospital
-
-
North West
-
Ndop, North West, Kamerun
- Ndop District Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- HIV-infected parents: Parents diagnosed with HIV infection or receiving HIV services in the hospital and consenting to participate will be eligible for enrollment in the study.
- Parents/guardians seeking care for their children in the hospital: Parents/guardians presenting at the hospital with sick children will be enrolled in the study irrespective of the motive of consultations for their children.
- Children of HIV infected parents: children of HIV infected parents aged between 6 weeks to 19 years old will be eligible for enrollment in the study. Parents/guardians consent will be required as well as assent of older kids.
- Children consulting in the hospital: Children aged 6 weeks to 19 years old consulting in the hospital for any reason will be eligible to participate in the study. Parents/guardians consent will be required as well as assent of older kids.
- HIV infected children: children (6weeks<years<19 years old) enrolled in HIV care in the hospital at least 2 years before the beginning of the project and after this beginning will be enrolled into the study to assess retention into care and factors associated with loss to follow up.
- Health personnel: Health personnel involved in children's consultations and consenting to participate will be enrolled in the study.
Exclusion Criteria:
- Refusal to participate: health personnel, parents/guardians, children not willing to participate will be excluded from the study
- HIV Status: Children with known HIV positive status will be excluded for HIV testing
- Age: Children below the age of 6 weeks or above 19 years will be excluded from the study
- Health conditions: parents who are critically ill or mentally unstable will be excluded from the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Výzkum zdravotnických služeb
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Intervention arm
The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS.
These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
|
The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS.
These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
|
Žádný zásah: Control arm
The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive.
These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians.
Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Yield
Časové okno: 6 months
|
Proportion of newly identified HIV cases amongst all children and adolescents eligible for HIV testing 2. Prevalence: proportion of HIV cases amongst children tested
|
6 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Prevalence
Časové okno: 6 months
|
Prevalence: proportion of HIV cases amongst children and adolescents tested for HIV
|
6 months
|
Linkage
Časové okno: 6 months
|
Linkage in care: proportion of pediatric HIV cases linked to care (CD4 testing and/or enrolment on ART)
|
6 months
|
Combined effect (tPITC+bPITC)
Časové okno: 6 months
|
Combined effect of tPITC and bPITC: Number of children tested positive and initiated on ART in the hospital during the study as compared to historical data.
|
6 months
|
Acceptability
Časové okno: 6 months
|
HIV testing acceptance rate: proportion of parents who accepted to have their children tested for HIV.
The acceptability assesses the attitude of parents/caregivers to opt in for HIV testing of their children.
|
6 months
|
feasibility
Časové okno: 6 months
|
HIV testing uptake: proportion of children tested amongst all eligible identified through parents in HIV care (for the targeted arm) or amongst all eligible children who visited the hospital (control arm) during the enrolment period.
The feasibility outcome variable assesses the capacity of the health facility to routinely test all eligible children
|
6 months
|
Retention
Časové okno: 24 months
|
Retention in care: proportion of cases still in care 12 and 24 months after enrolment
|
24 months
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Habakkuk Yumo, MD, MPH, Research for Development International
Publikace a užitečné odkazy
Obecné publikace
- Yumo HA, Ajeh RA, Sieleunou I, Ndenkeh JN Jr, Jordan MR, Sam-Agudu NA, Kuaban C, Loescher T. Parental and child-level predictors of HIV testing uptake, seropositivity and treatment initiation among children and adolescents in Cameroon. PLoS One. 2020 Apr 13;15(4):e0230988. doi: 10.1371/journal.pone.0230988. eCollection 2020.
- Yumo HA, Kuaban C, Ajeh RA, Nji AM, Nash D, Kathryn A, Beissner M, Loescher T. Active case finding: comparison of the acceptability, feasibility and effectiveness of targeted versus blanket provider-initiated-testing and counseling of HIV among children and adolescents in Cameroon. BMC Pediatr. 2018 Sep 25;18(1):309. doi: 10.1186/s12887-018-1276-7.
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- R4D0007/2015
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Pediatrická HIV infekce
-
Helsinki University Central HospitalUniversity of Turku; Oulu University Hospital; Kuopio University Hospital; Tampere...NáborHysterektomie | Antibiotika | Infection Post Op | ProfylaktickýFinsko
-
University of MalayaTeleflexNáborCLABSI - Central Line Associated Bloodstream InfectionMalajsie
-
Duke UniversityDokončenoCentral Line-associated Bloodstream Infection (CLABSI)Spojené státy
-
Catholic University of the Sacred HeartDokončenoCentral Line-associated Bloodstream Infection (CLABSI)
-
Sinocelltech Ltd.NáborHPV Infection Vaccine Safety SCT1000Čína
-
Johns Hopkins UniversityDokončenoCLABSI - Central Line Associated Bloodstream InfectionSpojené státy
-
Burdenko Neurosurgery InstituteDokončenoHyperglykémie | Kraniotomie | Infection Post OpItálie, Ruská Federace
-
National Taiwan University HospitalDokončenoCentral Line-associated Bloodstream Infection (CLABSI)Tchaj-wan
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyNáborCentral Line-associated Bloodstream Infection (CLABSI)Holandsko
-
Port Said UniversityNáborCentral Line-associated Bloodstream Infection (CLABSI)Egypt